Henrik Agersø
Novo Nordisk (Denmark)(DK)
Publications by Year
Research Areas
Hemophilia Treatment and Research, Blood Coagulation and Thrombosis Mechanisms, Growth Hormone and Insulin-like Growth Factors, Diabetes Treatment and Management, Pituitary Gland Disorders and Treatments
Most-Cited Works
- → Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration(2000)683 cited
- → The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men(2002)504 cited
- → Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects(2003)440 cited
- → Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects(2002)282 cited
- → Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes(2002)266 cited
- → Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide(2011)136 cited
- → Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients(2004)75 cited
- → Stochastic Differential Equations in NONMEM®: Implementation, Application, and Comparison with Ordinary Differential Equations(2005)74 cited
- → The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects(2006)73 cited
- → Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative(2003)68 cited